The biotechnology firm Helus Pharma, formerly known as Cybin, is accelerating its strategic pivot from a pure research entity to a commercially focused organization. This transition is gaining momentum through key executive appointments and encouraging clinical data, setting the stage for a pivotal year. The company’s preparations to bring its novel neuropsychiatry pipeline to market are now materializing.
A significant step in this direction was the appointment of Jill Conwell as Chief People Officer last Thursday. Conwell brings more than two decades of experience in building commercial teams within the life sciences sector. Her expertise is considered crucial as Helus Pharma anticipates several major clinical readouts over the next twelve months and must establish the organizational framework necessary for a potential product launch.
Clinical Pipeline Shows Substantial Promise
The company’s development programs are providing tangible evidence of progress. Most notably, on March 5, Helus Pharma announced positive Phase 2 trial results for its drug candidate HLP004, which is being developed for Generalized Anxiety Disorder. The data indicated a clinically meaningful reduction in symptoms after six weeks of treatment, with the therapeutic effect persisting at the six-month follow-up.
After half a year, 67% of treated patients were classified as responders, and 39% had achieved remission. The candidate addresses a significant unmet medical need, given that no new monotherapy for this condition has been approved in nearly two decades and approximately half of patients do not respond to standard treatments. The therapy also demonstrated a favorable tolerability profile, with no severe drug-related adverse events reported.
Should investors sell immediately? Or is it worth buying Cybin?
Financial and Operational Foundation Strengthened
Helus Pharma’s financial position supports its ambitious plans. The company is well-capitalized, with $248 million in liquid assets and a paid-off convertible bond. Furthermore, a strategic partnership with Thermo Fisher Scientific has been secured to ensure manufacturing capacity for late-stage clinical trials and potential commercial-scale production.
The corporate rebranding from Cybin to Helus Pharma, which coincided with its January listing on the Nasdaq, was implemented to better reflect this evolved commercial-stage strategy.
All Eyes on Flagship Depression Program
While the anxiety disorder program advances, the primary focus for investors remains the company’s lead asset, HLP003, for the treatment of Major Depressive Disorder. This compound is currently in a pivotal Phase 3 trial in the United States and has already received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA). A second Phase 3 study is slated to begin imminently across several European countries and Australia.
The next major catalyst for the company’s shares is clearly defined. Helus Pharma is scheduled to release the topline results from its Phase 3 trial for the depression medication HLP003 in the fourth quarter of 2026. With its clinical, organizational, and financial building blocks falling into place, the company is systematically preparing for a transformative commercial leap.
Ad
Cybin Stock: Buy or Sell?! New Cybin Analysis from March 13 delivers the answer:
The latest Cybin figures speak for themselves: Urgent action needed for Cybin investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 13.
Cybin: Buy or sell? Read more here...
